Mayo Clinic Laboratory and pathology research roundup: August 10

By Chantell Canfield • August 10, 2021

Share this:

The research roundup provides an overview of the past week’s research from Mayo Clinic Laboratories consultants, including featured abstracts and a complete list of published studies and reviews.

Featured Abstract

The CLL international prognostic index predicts outcomes in monoclonal B-cell lymphocytosis and rai 0 CLL.

The utility of the chronic lymphocytic leukemia-international prognostic index (CLL-IPI) in predicting outcomes of individuals with Rai 0 stage CLL and monoclonal B-cell lymphocytosis (MBL) is unclear. We identified 969 individuals (415 MBL and 554 Rai 0 CLL; median age, 64 years; 65% men) seen at Mayo Clinic between 1 January 2001 and 1 October 2018, and ascertained time to first therapy (TTFT) and overall survival (OS). After a median follow up of 7 years, the risk of disease progression needing therapy was 2.9%/y for MBL (median, not reached) and 5%/y for Rai 0 CLL (median, 10.4 years). Among patients with low, intermediate, and high/very high-risk CLL-IPI risk groups, the estimated 5-year risk of TTFT was 13.5%, 30%, and 58%, respectively, P< .0001 (c-statistic = 0.69); and the estimated 5-year OS was 96.3%, 91.5%, and 76%, respectively, P< .0001 (c-statistic = 0.65). In a multivariable analysis of absolute B-cell count with individual factors of the CLL-IPI, the absolute B-cell count was associated with shorter TTFT (hazard ratio [HR] for each 10 × 109/L increase: 1.31; P< .0001) and shorter OS (HR: 1.1; P = .02). The OS of the entire cohort was similar to that of the age- and sex-matched general population of Minnesota (P = .17), although Rai 0 CLL patients with high and very high-risk CLL-IPI score had significantly shorter OS (P= .01 and P= .0001, respectively). The results of this study demonstrate the ability of CLL-IPI to predict time from diagnosis to first treatment (an end point not affected by therapy) in a large cohort of patients whose only manifestation of disease is a circulating clonal lymphocyte population. Via PubMed

Read more.

Published to PubMed This Week

• Pulmonary arterial hypertension: diagnosis, treatment, and novel advances.
  American Journal of Respiratory and Critical Care Medicine
• LIN28 coordinately promotes nucleolar/ribosomal functions and represses the 2C-like transcriptional program in pluripotent stem cells.
  Protein and Cell
• Minimal residual disease in myeloma: application for clinical care and new drug registration.
  Clinical Cancer Research
• FBF1 deficiency promotes beiging and healthy expansion of white adipose tissue.
  Call Reports
• Borrelia mayonii - A cause of Lyme borreliosis that can be visualized by microscopy of thin blood films.
  Clinical Microbiology and Infection
• Mendelian randomisation study of smoking exposure in relation to breast cancer risk.
  British Journal of Cancer
• Harry Lee Parker: games lost and won on the playing fields of neurology.
  Mayo Clinic Proceedings, Innovations Qualities and Outcomes
• Disease outcomes and biomarkers of progression in smouldering Waldenström macroglobulinaemia.
  British Journal of Haematology
• De novo isolated myeloid sarcoma: comparative analysis of survival in 19 consecutive cases.
  British Journal of Haematology
• Updated results of the placebo-controlled, phase III JAKARTA trial of fedratinib in patients with intermediate-2 or high-risk myelofibrosis.
  British Journal of Haematology

Chantell Canfield

Chantell Canfield is a web content coordinator for Mayo Clinic Laboratories. She began working for Mayo Clinic in 2021.